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Background: There is conflicting evidence regarding the interaction among proton-pump inhibitors (PPIs), platelet P2Y12 inhibitors, and clinical 
outcomes in ACS patients.
methods: We evaluated 7243 ACS patients aged <75 y with UA/NSTEMI managed without revascularization enrolled in TRILOGY ACS, and analyzed 
the association between baseline PPI use and study treatment effect of prasugrel vs clopidogrel over 30 months. Adjusted hazard ratio (HR) 
estimates were derived using Cox proportional models weighted for inverse propensity of PPI use.
results: 1666 patients (23%) were taking a PPI at randomization. Those on PPIs at baseline were older, more likely to have NSTEMI and undergo 
angiography before randomization, and less likely to have prior heart failure (Table). Among those on PPI at baseline vs those not on PPI, there was 
no difference in adjusted risk of the primary efficacy endpoint of CV death, MI, or stroke with prasugrel (adjusted HR=1.11; 95% CI: 0.86-1.43), but 
there was a higher risk with PPI use with clopidogrel (adjusted HR=1.50; 95% CI: 1.19-1.89); interaction p=0.09.
conclusions: Patients with ACS managed medically and taking a PPI at baseline had a higher risk profile than those not on a PPI. Long-term risk 
of ischemic outcomes associated with PPI use was higher in those treated with clopidogrel vs those treated with prasugrel. Future analyses will 
evaluate this association with respect to the overall TRILOGY efficacy and safety results, including dedicated platelet function analyses. 
Selected baseline characteristics No PPI use (n=5577) PPI use (n=1666) P value
Median age, years (IQR) 62 (56, 68) 63 (57, 69) 0.001
Female sex, % 35.7 36.5 0.553
Disease classification, % <0.001
Unstable angina 34.4 26.4 -
NSTEMI 65.6 73.6 -
Prior heart failure, % 18.1 13.8 <0.001
Angiography performed, % 40.3 50.2 <0.001
